Linked Life Data

12957803

Source:http://linkedlifedata.com/resource/pubmed/id/12957803

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2003-9-5
pubmed:abstractText
Taxanes are major drugs in the treatment of breast metastatic cancer. Since 1990, the mechanisms implicated in carcinogenesis are better understood and the oncoprotein HER2 is a potential target. Trastuzumab is a monoclonal antibody that binds to this transmembrane glycoprotein. This antibody demonstrated a significant activity in clinical trials. In this review, we discuss the preclinical (mechanisms of action) and clinical data with the combination of trastuzumab and taxanes.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0007-4551
pubmed:author
pubmed:copyrightInfo
Copyright John Libbey Eurotext 2003.
pubmed:issnType
Print
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
614-22
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].
pubmed:affiliation
Centre René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France. m-capone@nantes.fnclcc.fr
pubmed:publicationType
Journal Article, English Abstract, Review